FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients
News
The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes Kisqali ... Read more